From The Industry Experts

  1. Inspection Facilitation Without Local MAH Presence 5/26/2026

    Local expertise and centralized oversight ensured compliant, well‑coordinated inspections across countries, reducing operational risk and client burden while maintaining consistent authority engagement.

  2. Continuity And Risk Mitigation Following Unexpected QPPV Resignation 5/26/2026

    Rapid escalation and clear interim governance ensured compliance and operational continuity following an unexpected QPPV resignation, reducing inspection risk during a critical pharmacovigilance transition.

  3. Transforming European Case Intake Operations 5/26/2026

    Centralized intake and semi‑automation brought clarity and control to European safety reporting, improving oversight, data quality, and compliance across multiple partners and countries.

  4. FDA's HALO Platform And Elsa 4.0: Five Critical Risks For Sponsors 5/26/2026

    Discover five critical risks created by HALO's architecture and Elsa 4.0's expanded capabilities. Then, learn how to implement practical safeguards sponsors to implement immediately.

  5. Biotech Ecosystem Helps Advance A New Approach To Inflammation Into Trials 5/26/2026

    BioAegis Therapeutics CEO Susan Levinson, Ph.D., talks about the role of partner and regulatory support in bringing their investigational immunotherapy into the clinic.

  6. Rethinking Patient Representation In Breast Cancer Trials For Better Outcomes 5/22/2026

    Broad patient representation in breast cancer trials is critical, and inclusive trial design improves data relevance, accelerates enrollment, and supports global approval and access.

  7. Faster Starts, Stronger Finish: Operational Excellence In NSCLC 5/22/2026

    In NSCLC trials, data‑driven site selection, streamlined protocols, efficient screening strategies, and proactive engagement can accelerate enrollment and improve trial efficiency across regions.

  8. How Adaptive Design Accelerates Early‑Phase NSCLC Development 5/22/2026

    Adaptive trial designs and an adaptive mindset enable non-small cell lung cancer (NSCLC) sponsors to optimize dose, respond to evolving expectations, and accelerate early‑phase development.

  9. Rare Disease Development: Navigating Small Populations And Complex Protocols 5/22/2026

    Learn how you can navigate the complexity of rare disease development with flexible trial design, integrated regulatory strategy, and data-driven execution built for small populations and global programs.

  10. The Compound Effect Of Specialized Knowledge 5/22/2026

    How does specialized knowledge compound over time into foresight, stronger execution, and more confident decision-making across the drug development lifecycle?